HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265

AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term.

On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy. Previously, on November 5, Piper Sandler reiterated a Buy rating on ABBV with a $289 price target, which reflects a 29.6% upside from its current levels.

Over the years, AbbVie Inc. (NYSE:ABBV) has built an impressive line-up of top-selling drugs. Skyrizi, an immunology treatment for arthritis and psoriasis, recorded a 46.8% growth in its sales in the third quarter of 2025 to $4.7 billion. Rinvoq, another immunology drug, reported $2.18 billion in sales, up 35.3% YoY. Similarly, Humira, which is used to treat plaque psoriasis, posted $993 million in revenues, which showed a staggering 55.4% growth from the previous year.

Due to these exceptional results, AbbVie Inc. (NYSE:ABBV)’s management sees further growth in these drugs’ performance. The company expects Rinvoq to generate $11 billion in revenues by 2027, with Skyrizi projected to reach $20 billion. Though the guidance looks overly ambitious, the company’s strong portfolio and its efforts to expand its pipelines through acquisitions make it achievable. In addition, AbbVie Inc. (NYSE:ABBV)’s pipeline across multiple therapeutic areas is promising as well.

On October 31, AbbVie Inc. (NYSE:ABBV)’s board raised the quarterly dividend by 5.5% to $1.73 per share, up from $1.64. That brings the annual payout to $6.92 per share and marks the company’s 53rd consecutive year of dividend growth.

AbbVie Inc. (NYSE:ABBV) is an American pharmaceutical company known for producing treatments that address a wide range of medical conditions.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 11 Worst Performing Dividend Stocks Year-to-Date.

Disclosure: None.